hydroxyzine has been researched along with Electrocardiogram QT Prolonged in 5 studies
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.
hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this paper, we will report a case of drug-induced long QT syndrome associated with an H(1)-receptor antagonist, hydroxyzine, in which a mutation was identified in the HERG gene." | 7.74 | Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. ( Ashihara, T; Ding, WG; Higashi, Y; Horie, M; Ito, M; Itoh, H; Matsuura, H; Nagaoka, I; Oka, Y; Sakaguchi, T; Takeyama, Y; Tsuji, K; Yumoto, Y; Zenda, N, 2008) |
| "Regulatory advisories on hydroxyzine and risk of QT prolongation and Torsade de pointes (TdP) were issued in the UK in April 2015 and Canada in June 2016." | 4.12 | Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. ( Ahmed, B; Bero, L; De Bruin, ML; Dormuth, CR; Gnjidic, D; Hallgreen, CE; Kemp-Casey, A; Kristiansen, SB; Lexchin, J; Lopert, R; Mangin, D; Mintzes, B; Morrow, RL; Pearson, SA; Puil, L; Roughead, EE; Sarpatwari, A; Sketris, I; Souverein, PC, 2022) |
| " In this paper, we will report a case of drug-induced long QT syndrome associated with an H(1)-receptor antagonist, hydroxyzine, in which a mutation was identified in the HERG gene." | 3.74 | Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. ( Ashihara, T; Ding, WG; Higashi, Y; Horie, M; Ito, M; Itoh, H; Matsuura, H; Nagaoka, I; Oka, Y; Sakaguchi, T; Takeyama, Y; Tsuji, K; Yumoto, Y; Zenda, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morrow, RL | 1 |
| Mintzes, B | 1 |
| Souverein, PC | 1 |
| Hallgreen, CE | 1 |
| Ahmed, B | 1 |
| Roughead, EE | 1 |
| De Bruin, ML | 1 |
| Kristiansen, SB | 1 |
| Lexchin, J | 1 |
| Kemp-Casey, A | 1 |
| Sketris, I | 1 |
| Mangin, D | 1 |
| Pearson, SA | 1 |
| Puil, L | 1 |
| Lopert, R | 1 |
| Bero, L | 1 |
| Gnjidic, D | 1 |
| Sarpatwari, A | 1 |
| Dormuth, CR | 1 |
| Kobayashi, K | 1 |
| Omuro, N | 1 |
| Takahara, A | 1 |
| Vigne, J | 1 |
| Alexandre, J | 1 |
| Fobe, F | 1 |
| Milliez, P | 1 |
| Loilier, M | 1 |
| Fedrizzi, S | 1 |
| Coquerel, A | 1 |
| Mistraletti, G | 1 |
| Iapichino, G | 1 |
| Sakaguchi, T | 1 |
| Itoh, H | 1 |
| Ding, WG | 1 |
| Tsuji, K | 1 |
| Nagaoka, I | 1 |
| Oka, Y | 1 |
| Ashihara, T | 1 |
| Ito, M | 1 |
| Yumoto, Y | 1 |
| Zenda, N | 1 |
| Higashi, Y | 1 |
| Takeyama, Y | 1 |
| Matsuura, H | 1 |
| Horie, M | 1 |
5 other studies available for hydroxyzine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study.
Topics: Canada; Cohort Studies; DNA-Binding Proteins; Electrocardiography; Humans; Hydroxyzine; Long QT Synd | 2022 |
The conventional antihistamine drug cyproheptadine lacks QT-interval-prolonging action in halothane-anesthetized guinea pigs: comparison with hydroxyzine.
Topics: Action Potentials; Anesthesia; Animals; Cyproheptadine; Dose-Response Relationship, Drug; Electrocar | 2014 |
QT prolongation induced by hydroxyzine: a pharmacovigilance case report.
Topics: Aged; Histamine H1 Antagonists; Humans; Hydroxyzine; Long QT Syndrome; Male; Pharmacovigilance | 2015 |
Hydroxyzine and QTc interval: drugs without sin cast the first stone!
Topics: Critical Care; Humans; Hydroxyzine; Long QT Syndrome; Pharmacovigilance; Premedication | 2016 |
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation.
Topics: Adult; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Female; Gene Expression R | 2008 |